Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
Telios Pharma, Inc. · NCT06686472
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 66
- US sites recruiting
- 1
- Study start
- October 3, 2024
- Record last updated
- November 13, 2024
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.
The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
Being studied: TL-925; Placebo
Conditions: Allergic Conjunctivitis
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Individuals aged 18 years or older
- Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study.
- Documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at Visit 1 or within the past 60 months.
- Calculated best-corrected visual activity of 0.7 LogMAR or better
- Positive bilateral CAC reaction
Exclusion Criteria
- Any systemic or ocular disease currently producing ocular redness and/or ocular discomfort, or that may interfere with the conduct of the study.
- Any ocular surgical intervention within the last 3 months OR refractive surgery within the last 6 months
- Any ongoing ocular infection (bacterial, viral or fungal)
Recruiting US locations
Telios Investigative Site
Memphis, TN 38119
Study contacts (from the official record)
- John Mei · (650) 542-0136 · jmei@teliospharma.com
- Yulia Khalina · ykhalina@teliospharma.com